Proctor, Toby Joseph;
(2019)
Translational process engineering for tissue engineered hollow organ advanced therapy investigational medicinal products.
Doctoral thesis (Eng.D), UCL (University College London).
Preview |
Text
Proctor_EngD_2018_CORRECTED_FINALv2.pdf Download (9MB) | Preview |
Abstract
Tissue engineering has experienced increasing exposure and translational success in recent times, with tissue engineered products accounting for more than a quarter of approved advanced therapy medicinal products within Europe. Hollow organs represent a key target for developing novel therapies, typified by the recent success reported for tissue engineered hemilaryngeal replacements in a preclinical study. This thesis investigates the translational process engineering required to progress from a preclinical, good laboratory practice (GLP) process, to one that is compliant with good manufacturing practice (GMP) guidelines and suitable for clinical manufacture. A GLP decellularisation protocol was translated to conform to GMP-guidelines by modifying the existing standard operating procedure, and adapting an off-the-shelf bioreactor to form a closed-system for aseptic processing. The process was successfully validated for aseptic operation and decellularisation efficacy evaluated, relative to the preclinical process. The decellularised, human hemilarynx scaffolds produced were demonstrated to support bone marrow mesenchymal stromal cells (BM-MSCs) up to product release. A bespoke, modular bioreactor was designed and fabricated to enable manufacture of hemilarynges at scale. The bioreactor was successfully validated for aseptic use, whilst biocompatibility testing indicated no preclusion to use with BM-MSCs or epithelial cells. Proof-of-principle data supported the concept of epithelial sheet production inside the bioreactor, utilising a sheet-specific cassette. The bioreactor was retrospectively adapted to enable closed-system decellularisation processing of a third tissue-type, juvenile oesophagus. Acellular scaffold biomolecular composition and biomechanics were characterised, preceding implantation in a large-animal model. A second, bespoke bioreactor was designed, manufactured and employed to improve the manufacturing process. The combined human larynx data supported the award of a clinical trial authorisation, whilst the oesophageal work is now transitioning to a pivotal animal study. These findings support the application of bespoke bioreactor systems in process closure and translation towards robust, regulatory compliant, manufacturing processes for tissue engineered products.
| Type: | Thesis (Doctoral) |
|---|---|
| Qualification: | Eng.D |
| Title: | Translational process engineering for tissue engineered hollow organ advanced therapy investigational medicinal products |
| Event: | UCL (University College London) |
| Open access status: | An open access version is available from UCL Discovery |
| Language: | English |
| Additional information: | Copyright © The Author 2019. Original content in this thesis is licensed under the terms of the Creative Commons Attribution 4.0 International (CC BY 4.0) Licence (https://creativecommons.org/licenses/by/4.0/). Any third-party copyright material present remains the property of its respective owner(s) and is licensed under its existing terms. Access may initially be restricted at the author’s request. |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute > Research Department of Haematology |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10072711 |
Archive Staff Only
 |
View Item |
